Journal Watch
- PDF / 126,553 Bytes
- 6 Pages / 612.28 x 790.87 pts Page_size
- 96 Downloads / 158 Views
NEWS
ยช 2011 Adis Data Information BV. All rights reserved.
Journal Watchy Contents 1. Highlights from Adis Journals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 1.1 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 1.2 Cardiovascular Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 1.3 Infectious Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 1.4 Psychiatric Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 1.5 Skin Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126 2. News from Other Sources . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
1. Highlights from Adis Journals
evaluation; however, it is possible that these patients would need to continue therapy indefinitely.
1.1 Cancer
Ganjoo KN, Shreyaskumar P. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Drugs 2011; 71 (3): 321-30
Current and Emerging Pharmacologic Treatments for Gastrointestinal Stromal Tumor
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, previously classified as leiomyosarcomas. Most GISTs express KIT and the majority of patients have mutations in the KIT gene. The most common KIT mutation occurs in the juxtamembrane domain of exon 11. These mutations lead to cellular proliferation and survival. GISTs with exon 11 mutations respond better to tyrosine kinase inhibitors (TKIs) than those with exon 9 mutations. Most KIT-negative GISTs express platelet-derived growth factor receptor (PDGFR)-a; however, a small percentage of GISTs are negative for both KIT and PDGFRa. Imatinib and other TKIs have dramatically improved the outcome of patients with metastatic GISTs. Newer and more advanced TKIs are under intensive investigation as eventually all GIST patients develop resistant tumors. In addition, these drugs can be utilized in the preoperative setting for patients with unresectable localized tumors or those at high risk of surgical morbidity. TKIs have been given in the adjuvant setting for patients with resected tumors at high risk of recurrence. The duration
Data Loading...
